86 related articles for article (PubMed ID: 30067206)
1. [NK cells: a major role in the antitumoral immunomodulation in CML].
Toubert A; Turhan A; Guerci-Bresler A; Dulphy N; Réa D
Med Sci (Paris); 2018; 34(6-7):540-546. PubMed ID: 30067206
[TBL] [Abstract][Full Text] [Related]
2. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
3. Role of cancer immunology in chronic myelogenous leukemia.
Ureshino H; Shindo T; Kimura S
Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
[TBL] [Abstract][Full Text] [Related]
4. The role of autologous natural killer cells in chronic myelogenous leukemia.
Pierson BA; Miller JS
Leuk Lymphoma; 1997 Nov; 27(5-6):387-99. PubMed ID: 9477121
[TBL] [Abstract][Full Text] [Related]
5. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
6. The role of natural killer cells in the treatment of chronic myeloid leukemia.
Silla LM; Whiteside TL; Ball ED
J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
[TBL] [Abstract][Full Text] [Related]
7. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
9. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
11. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.
Kijima M; Gardiol N; Held W
PLoS One; 2011; 6(11):e27639. PubMed ID: 22132120
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
[TBL] [Abstract][Full Text] [Related]
15. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Huuhtanen J; Adnan-Awad S; Theodoropoulos J; Forstén S; Warfvinge R; Dufva O; Bouhlal J; Dhapola P; Duàn H; Laajala E; Kasanen T; Klievink J; Ilander M; Jaatinen T; Olsson-Strömberg U; Hjorth-Hansen H; Burchert A; Karlsson G; Kreutzman A; Lähdesmäki H; Mustjoki S
Leukemia; 2024 Jan; 38(1):109-125. PubMed ID: 37919606
[TBL] [Abstract][Full Text] [Related]
16. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
17. Studies on natural killer cells in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake RJ; Advani S; Gangal SG
Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
19. [Progress in laboratory medicine in chronic myeloid leukemia].
Miura A
Rinsho Byori; 1998 Dec; 46(12):1226-31. PubMed ID: 9916508
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]